KATP channel inhibitors, including sulfonylureas and glinides widely used to treat type 2 diabetes, are known to act as pharmacochaperones to correct KATP trafficking defects caused by mutations in the SUR1-TMD0 domain (17, 19, 28, 29). Here, ABCC8 is linked to type 2 diabetes mellitus.